0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-68.35%PremiumOct 18, 2024Expiry Date2.03Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.75Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Eledon Pharmaceuticals Stock Discussion
Eledon Announces Completion of Enrollment in Phase 2 Bestow Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
Benzinga· 2 mins ago
Pull up Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), this company has made headlines with its announcement of securing an oversubscribed $50 million private placement. This strategic financial endeavor is not just a testament to the confidence that institutional and accredited healthcar...
Eledon Pharmaceuticals Announced A Private Investment Of Approximately $50M, With Sale Of 13.1M Shares At $2.37/Share And Pre-funded Warrants At $2.369/Underlying Share, Which Are Exercisable To Purchase 7.99M Shares
No comment yet